Please login to the form below

Not currently logged in
Email:
Password:

Actelion to buy Ceptaris - if FDA backs its cancer treatment

Acquisition contingent on Valchlor approval in rare lymphoma

Actelion HQ Switzerland

Actelion is set to acquire US-based biopharma Ceptaris, but only if US regulators approve Ceptaris' cancer treatment Valchlor.

The deal will see Switzerland-based Actelion pay $250m for Ceptaris, as well as further milestones, with Actelion to take full control of its target.

This is all contingent on whether or not the US Food and Drug Administration (FDA) decides to back Valchlor, which is a proprietary gel formulation of mechlorethamine hydrochloride intended for use in the treatment of patients with early-stage mycosis fungoides-type cutaneous T-cell lymphoma.

The disease is a rare type of cancer involving the uncontrolled growth of T cells within the skin for which there are currently no specific drug treatments approved by the FDA.

Ceptaris has already received a knockback from the FDA for Valchlor in May 2012, when the company received a Complete Response Letter explaining the drug could not be approved based on current data.

The company resubmitted a New Drug Application early this year, however, with the FDA also granting the drug orphan status due to the rarity of its proposed indication.

The FDA is now in the late stages of its review process for Valchlor, and a final decision on whether the drug should be granted marketing approval is expected by the end of August 2013.

“Should the FDA approve Valchlor and Actelion acquire Ceptaris, we would be able to offer this meaningfully differentiated medicine to patients who today are dependent on formulations prepared locally by compounding pharmacies in a non-standardised environment,” said Actelion's CEO Dr Jean-Paul Clozel.

“At the same time, we would leverage our existing knowhow and infrastructure in the fields of orphan and ultra-orphan indications when appropriately commercialising Valchlor to specialists in the field of dermatology and oncology."

Valchlor is also under review in Europe where it is also considered an orphan drug.

1st August 2013

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics